A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

• Published in: The New England journal of medicine Vol. 382; no. 2; pp. 120 - 129
• Main Authors: Dangas, George D, Tijssen, Jan G.P, Wöhrle, Jochen, Søndergaard, Lars, Gilard, Martine, Möllmann, Helge, Makkar, Raj R, Herrmann, Howard C, Giustino, Gennaro, Baldus, Stephan, De Backer, Ole, Guimarães, Ana H.C, Gullestad, Lars, Kini, Annapoorna, von Lewinski, Dirk, Mack, Michael, Moreno, Raúl, Schäfer, Ulrich, Seeger, Julia, Tchétché, Didier, Thomitzek, Karen, Valgimigli, Marco, Vranckx, Pascal, Welsh, Robert C, Wildgoose, Peter, Volkl, Albert A, Zazula, Ana, van Amsterdam, Ronald G.M, Mehran, Roxana, Windecker, Stephan
• Format: Journal Article Web Resource
• Language: English
• Published: United States Massachusetts Medical Society 09.01.2020
• Subjects: 9NDF7JZ4M3 (Rivaroxaban); A74586SNO7 (Clopidogrel); Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin - adverse effects; Aspirin - therapeutic use; Aspirin/adverse effects/therapeutic use; Atrial Fibrillation - drug therapy; Bleeding; Cardiac arrhythmia; Cardiovascular & respiratory systems; Cardiovascular Diseases - mortality; Clopidogrel; Clopidogrel - adverse effects; Clopidogrel - therapeutic use; Clopidogrel/adverse effects/therapeutic use; Confidence intervals; Death; Drug Therapy, Combination; Embolisms; Factor Xa Inhibitors; Factor Xa Inhibitors - adverse effects; Factor Xa Inhibitors - therapeutic use; Factor Xa Inhibitors/adverse effects/therapeutic use; Female; Heart Valve Prosthesis; Hemorrhage - chemically induced; Human health sciences; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Platelet Aggregation Inhibitors; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Platelet Aggregation Inhibitors/adverse effects/therapeutic use; R16CO5Y76E (Aspirin); Rivaroxaban - adverse effects; Rivaroxaban - therapeutic use; Rivaroxaban/adverse effects/therapeutic use; Safety; Sciences de la santé humaine; Statistical analysis; Systèmes cardiovasculaire & respiratoire; Thromboembolism; Thromboembolism - mortality; Thrombosis; Transcatheter Aortic Valve Replacement
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1911425

Patients who had undergone successful TAVR were randomly assigned to receive either a rivaroxaban-based antithrombotic regimen or an antiplatelet-based antithrombotic regimen. At 17 months, the primary outcome of death or thromboembolic complications occurred more frequently with rivaroxaban.